How EMPAVELI can help | LDH NORMALIZATION
LDH normalization in people with and without previous C5i treatment
This information is for observation only and no conclusions can be made on the effect of EMPAVELI on LDH normalization. No comparisons can be made between those taking EMPAVELI and those taking eculizumab in PEGASUS or those in the control arm (excluding C5i) in PRINCE.
The majority of people taking EMPAVELI reduced their LDH levels to within the normal range (113-226 U/L).
Nearly 2/3 of people taking EMPAVELI reduced their LDH levels to within the normal range (113-226 U/L).
Jillian is an adult with PNH taking EMPAVELI.
In people who had previously received a C5i (PEGASUS)
In people who had never received a C5i (PRINCE)
At Week 16 in PEGASUS
At Week 26 in PRINCE
80
80
70
70
71%
of people taking EMPAVELI achieved LDH normalization
of people taking EMPAVELI achieved LDH normalization
60
60
66%
50
50
40
40
30
30
20
20
15%
10
10
0%
0
0
EMPAVELI n=41
eculizumab n=39
EMPAVELI n=35
Control arm (excluding C5i) n=18
Long-term Hb and LDH data
see additional data
IMPORTANT SAFETY INFORMATION What is the most important information I should know about EMPAVELI? EMPAVELI is a medicine that can affect your immune system and can lower the ability of your immune system to fight infections.
C5i=C5 inhibitor; Hb=hemoglobin; LDH=lactate dehydrogenase; PNH=paroxysmal nocturnal hemoglobinuria.
Please see full Important Safety Information, including Boxed WARNING regarding risk of serious infections, on pages 38-39, and the full Prescribing Information and Medication Guide.
24
25
Made with FlippingBook flipbook maker